Blytt Kjersti M, Husebo Bettina, Flo Elisabeth, Bjorvatn Bjørn
Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway.
Centre for Elderly and Nursing Home Medicine, University of Bergen, Bergen, Norway.
Front Psychol. 2018 Feb 13;9:134. doi: 10.3389/fpsyg.2018.00134. eCollection 2018.
Previous research indicates that pain treatment may improve sleep among nursing home patients. We aimed to investigate the long-term effect of pain treatment on 24-h sleep patterns in patients with comorbid depression and dementia. A 13-week, multicenter, parallel-group, double-blind, placebo-controlled randomized clinical trial conducted between August 2014 and September 2016. Long-term patients from 47 nursing homes in Norway. We included 106 patients with comorbid dementia and depression according to the and the Patients who were not using analgesics were randomized to receive either paracetamol (3 g/day) or placebo tablets. Those who already received pain treatment were randomized to buprenorphine transdermal system (maximum 10 μg/h/7 days) or placebo transdermal patches. Sleep was assessed continuously for 7 days by actigraphy, at baseline and in week 13. Total sleep time (TST), sleep efficiency (SE), sleep onset latency (SOL), wake after sleep onset (WASO), early morning awakening (EMA), and number of wake bouts (NoW) were evaluated. In addition, daytime total sleep time (DTS) was estimated. Pain was assessed with (MOBID-2). The linear mixed model analyses for TST, SE, SOL, WASO, EMA, NoW and DTS showed no statistically significant differences between patients who received active pain treatment and those who received placebo. subgroup analyses showed that there were no statistically significant differences between active treatment and placebo from baseline to week 13 in patients who were in pain (MOBID-2 ≥ 3) at baseline, or in patients who had poor sleep (defined as SE < 85%) at baseline. Patients who received active buprenorphine showed an increase in TST and SE compared to those who received active paracetamol. The main analyses showed that long-term pain treatment did not improve sleep as measured with actigraphy. Compared to paracetamol, TST and SE increased among patients who received buprenorphine. This could indicate that some patients had beneficial effects from the most potent pain treatment. However, based on the present findings, long-term pain treatment is not recommended as a strategy to improve sleep. Clinical Trial https://clinicaltrials.gov/ct2/show/NCT02267057.
先前的研究表明,疼痛治疗可能会改善养老院患者的睡眠。我们旨在调查疼痛治疗对合并抑郁症和痴呆症患者24小时睡眠模式的长期影响。这是一项在2014年8月至2016年9月期间进行的为期13周的多中心、平行组、双盲、安慰剂对照随机临床试验。研究对象为挪威47家养老院的长期患者。根据[相关标准],我们纳入了106例合并痴呆症和抑郁症的患者。未使用镇痛药的患者被随机分为接受对乙酰氨基酚(3克/天)或安慰剂片。那些已经接受疼痛治疗的患者被随机分为接受丁丙诺啡透皮系统(最大剂量10μg/小时/7天)或安慰剂透皮贴剂。在基线和第13周时,通过活动记录仪连续7天评估睡眠情况。评估总睡眠时间(TST)、睡眠效率(SE)、入睡潜伏期(SOL)、睡眠中觉醒时间(WASO)、清晨觉醒(EMA)和觉醒次数(NoW)。此外,还估计了白天总睡眠时间(DTS)。使用[相关量表](MOBID - 2)评估疼痛。对TST、SE、SOL、WASO、EMA、NoW和DTS的线性混合模型分析显示,接受积极疼痛治疗的患者与接受安慰剂的患者之间没有统计学上的显著差异。亚组分析显示,在基线时疼痛(MOBID - 2≥3)的患者或基线时睡眠不佳(定义为SE < 85%)的患者中,从基线到第13周,积极治疗组与安慰剂组之间没有统计学上的显著差异。与接受积极对乙酰氨基酚治疗的患者相比,接受积极丁丙诺啡治疗的患者TST和SE有所增加。主要分析表明,长期疼痛治疗并未改善通过活动记录仪测量的睡眠情况。与对乙酰氨基酚相比,接受丁丙诺啡治疗的患者TST和SE有所增加。这可能表明一些患者从最强效的疼痛治疗中获得了有益效果。然而,基于目前的研究结果,不建议将长期疼痛治疗作为改善睡眠的策略。临床试验https://clinicaltrials.gov/ct2/show/NCT02267057 。